Mohamed, Aly FahmyAbdulall, Abeer KhairyTawfick, Mahmoud Mohamed)Abdullatif, Amal Osman2019-12-142019-12-142016-01Nanocapsulated Rift Valley Fever vaccine candidates and relative immunological and histopathological reactivity in out bred Swiss mice By: Abd El- Razek, N. E. E. - D; Shoman, S. A.; Mohamed, A. F. Journal of Vaccines & Vaccination Volume: 02 Issue: 01 Published: 2011 URL: http://dx.doi.org/ Times Cited: 1 2. New Trends in Cancer Therapy and Antiviral Drug Research By: Alyan, M.; Shalaby, M.; El- Sanousi, A.; et al. International Journal of Advanced Research Volume: 4 Issue: 5 Pages: 698-710 Published: 2016 URL: http://dx.doi.org/ [Show additional data] Times Cited: 1 3. Antiviral and Anticancer Potentials of Snake and ScorpionVenom Derivatives By: Alyan, MS; Shalaby, MA; El-Sanousi, AA; et al. Inventi Rapid: Molecular Pharmacology Volume: 2014 Issue: 2 Pages: 1-11 Published: 2014 [Show additional data] Times Cited: 2 4. IMMUNOGENICITY OF A VIRAL MODEL VACCINE AFTER DIFFERENT INACTIVATION PROCEDURES By: BACHMANN, MF; BAST, C; HENGARTNER, H; et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY Volume: 183 Issue: 2 Pages: 95-104 Published: MAY 1994 Times Cited: 29 5. A STUDY OF THE EFFECT OF CHEMICAL INACTIVANTS ON THE EPITOPES OF RIFT-VALLEY FEVER VIRUS GLYCOPROTEINS USING MONOCLONAL-ANTIBODIES By: BLACKBURN, NK; BESSELAAR, TG JOURNAL OF VIROLOGICAL METHODS Volume: 33 Issue: 3 Pages: 367-374 Published: AUG 1991 Times Cited: 26 6. Review of accidents caused by incomplete inactivation of viruses By: Brown, F. Developments in biological standardization Volume: 81 Pages: 103- 107 Published: 1992 Times Cited: 2 7. PRINCIPLES OF SELECTIVE INACTIVATION OF VIRAL GENOME .7. SOME PECULIARITIES IN DETERMINATION OF VIRAL SUSPENSION INFECTIVITY DURING INACTIVATION BY CHEMICAL-AGENTS By: BUDOWSKY, EI; FRIEDMAN, EA; ZHELEZNOVA, NV VACCINE Volume: 9 Issue: 7 Pages: 473-476 Published: JUL 1991 Times Cited: 9 8. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine By: Cederna, JB; Klinzman, D; Stapleton, JT VACCINE Volume: 18 Issue: 9-10 Pages: 892-898 Published: DEC 10 1999 Times Cited: 25 9. Comparison of beta-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus By: Chowdhury, Pritom; Topno, Rashmee; Khan, Siraj A.; et al. ADVANCES IN VIROLOGY Article Number: UNSP 616898 Published: 2015 Times Cited: 3 10. Title: [not available] By: Doyle, A.; Griffiths, J. B. Cell and tissue culture: laboratory procedures in biotechnology Published: 1998 Publisher: John Wiley & Sons Ltd, West Sussex Times Cited: 60 11. Snake venom L-amino acid oxidases By: Du, XY; Clemetson, KJ TOXICON Volume: 40 Issue: 6 Pages: 659-665 Article Number: PII S0041-0101(02)00102-2 Published: JUN 2002 Times Cited: 236 12. Title: [not available] By: Ecobichon, D. J. The Basis of the Toxicity Testing Published: 1997 Publisher: CRC Press LLC, Boca Raton, FL Times Cited: 11 13. Hepatitis A: Epidemiology and prevention in developing countries By: Franco, Elisabetta; Meleleo, Cristina; Serino, Laura; et al. WORLD JOURNAL OF HEPATOLOGY Volume: 4 Issue: 3 Pages: 68-73 Published: MAR 27 2012 Times Cited: 112 14. IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA-VIRUS VIROSOME VACCINE DELIVERY SYSTEM FOR IMMUNIZATION AGAINST HEPATITIS-A By: GLUCK, R; MISCHLER, R; BRANTSCHEN, S; et al. JOURNAL OF CLINICAL INVESTIGATION Volume: 90 Issue: 6 Pages: 2491-2495 Published: DEC 1992 Times Cited: 113 15. Aluminum compounds as vaccine adjuvants By: Gupta, RK ADVANCED DRUG DELIVERY REVIEWS Volume: 32 Issue: 3 Pages: 155-172 Published: JUL 6 1998 Times Cited: 373 16. Hepatitis viruses. By: Harrison, T. J.; Dusheiko, G. M.; Zuckerman, A. J. Principles and practice of clinical virology Issue: Ed. 6 Pages: 273-320 Published: 2009 Times Cited: 7 17. Snake Venom L-Amino Acid Oxidases: Trends in Pharmacology and Biochemistry By: Izidoro, Luiz Fernando M.; Sobrinho, Juliana C.; Mendes, Mirian M.; et al. BIOMED RESEARCH INTERNATIONAL Article Number: 196754 Published: 2014 Times Cited: 66 18. Epidemiology of hepatitis A virus in Africa among persons aged 1-10 years: a systematic review protocol By: Kanyenda, Tiwonge J.; Abdullahi, Leila H.; Hussey, Gregory D.; et al. SYSTEMATIC REVIEWS Volume: 4 Article Number: 129 Published: 2015 Times Cited: 4 19. Hepatitis vaccines By: Karayiannis, P; Main, J; Thomas, HC BRITISH MEDICAL BULLETIN Volume: 70 Issue: 1 Pages: 29-49 Published: 2004 Times Cited: 10 20. Antibacterial properties of l-amino acid oxidase: mechanisms of action and perspectives for therapeutic applications By: Kasai, Kosuke; Ishikawa, Takashi; Nakamura, Toshiya; et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY Volume: 99 Issue: 19 Pages: 7847-7857 Published: OCT 2015 Times Cited: 13 21. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease By: Keeffe, EB; Iwarson, S; McMahon, BJ; et al. HEPATOLOGY Volume: 27 Issue: 3 Pages: 881-886 Published: MAR 1998 Times Cited: 173 22. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy By: Lappin, MB; Campbell, JDM BLOOD REVIEWS Volume: 14 Issue: 4 Pages: 228-239 Published: DEC 2000 Times Cited: 39 23. Aluminium adjuvants - in retrospect and prospect By: Lindblad, EB VACCINE Volume: 22 Issue: 27-28 Pages: 3658-3668 Published: SEP 9 2004 Times Cited: 218 24. In vitro inactivation of the rabies virus by ascorbic acid By: Madhusudana, SN; Shamsundar, R; Seetharaman, S INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES Volume: 8 Issue: 1 Pages: 21-25 Published: JAN 2004 Times Cited: 14 25. Introduction to cell and tissue culture: theory and technique By: Mather, JP; Roberts, PE. Introductory cell and molecular biology techniques Published: 1998 Publisher: Plenum Press, New York and London Times Cited: 62 26. Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review. (View record in MEDLINE) By: Meenakshisundaram, Ramachandran; Sweni, Shah; Thirumalaikolundusubramanian, Ponniah AIDS research and therapy Volume: 6 Pages: 25 Published: 2009 Nov 19 Times Cited: 12 27. Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization By: Mitchell, LA; Galun, E VACCINE Volume: 21 Issue: 13-14 Pages: 1527-1538 Article Number: PII S0264-410X(02)00699-0 Published: MAR 28 2003 Times Cited: 7 28. VIRUS-INACTIVATING EFFECT OF ASCORBIC-ACID .13. VIRUS-INACTIVATING EFFECT OF D-ISOASCORBIC ACID By: MURATA, A; KAWASAKI, M; MOTOMATSU, H; et al. JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY Volume: 32 Issue: 6 Pages: 559-567 Published: DEC 1986 Times Cited: 5 29. IN-VITRO INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY ASCORBIC-ACID By: RAWAL, BD; BARTOLINI, F; VYAS, GN BIOLOGICALS Volume: 23 Issue: 1 Pages: 75-81 Published: MAR 1995 Times Cited: 8 30. A simple method of estimating fifty per cent endpoints (View record in BIOSIS Citation Index) By: REED, L. J.; MUENCH, H. AMER JOUR HYG Volume: 27 Issue: (3) Pages: 493-497 Published: 19381338-5178https://doi.org/10.15414/jmbfs.2016/17.6.3.937-942https://t.ly/L93NYAccession Number: WOS:000458342200012Hepatitis A virus (HAV) is one of the most common causes of acute viral hepatitis worldwide. Formaldehyde is the currently used inactivating agent in HAV vaccine processing despite of its adverse effects. The current study aimed to evaluate both L-amino acid oxidase (LAO) and L-ascorbic acid (LAA) as alternative inactivants for HAV and the immunogenicity of inactivated HAV in mice. Vero cell line was used for cultivation of HAV. The cytotoxicity of LAO and LAA on Vero cells was evaluated using 3-(4,5-dimethylthiazol-2-yl) 2,5 diphenyl tetrazolium bromide (MTT) assay. The immunogenicity of each LAO- and LAA-inactivated HAV was examined in parallel with reference HAV vaccine in mice. Humoral (total IgG) and cellular immune responses (IFN-gamma and IL-5) were evaluated in mice sera using ELISA. Both LAO and LAA could efficiently inactivate HAV within 30 and 36 hrs post treatment, respectively, at concentrations of 0.4 mu gm/ml of LAO and 1.5 mg/ml of LAA. Inactivated vaccines were immunogenic to mice on both the humoral and cellular levels. LAO prepared vaccines showed a more promising immune reactivity than LAA prepared ones and alum-adsorbed vaccines were more immunogenic than non-adjuvanted ones. In conclusion, data recorded suggest that both LAO and LAA can be used as inactivating agents for HAV grown in cell culture. LAA- and LAO-inactivated HAV can be potential vaccines as they provide effective humoral and cellular immune responses comparable to that of the reference vaccine. The stability of test vaccines is recommended to be traced at different thermal conditions, in addition to different stabilizers and different pharmaceutical formulations must be tested trying to produce a lyophilized formula for long-term stability.en-USPREVENTIONINFECTIVITYEPIDEMIOLOGYIMMUNIZATIONIN-VITRO INACTIVATIONCELLULAR IMMUNE-RESPONSESalumL-ascorbic acidL-amino oxidasevirus inactivationvaccineHepatitis AArticlehttps://doi.org/10.15414/jmbfs.2016/17.6.3.937-942